Tag:
Trophos
Latest Headlines
Latest Headlines
PhIII ALS failure costs Trophos a $250M buyout deal with Actelion
France's Trophos says that a Phase III study of its lead drug for ALS (Lou Gehrig's disease) failed to hit its primary endpoint, and the swing and a miss will cost its investors up to $250 million.
Actelion gets option to buy Trophos for up to $250M
Switzerland's Actelion has paid €10 million for an exclusive option to acquire France's Trophos, a private development company whose lead drug, olesoxime, is in Phase III testing as a therapy
